This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioReference Laboratories, Inc. Provides Guidance For FY13 And Q4FY13 Anticipated Results

ELMWOOD PARK, N.J., Nov. 27, 2013 (GLOBE NEWSWIRE) -- BioReference Laboratories, Inc. (Nasdaq:BRLI) today provided a preview of revenues and earnings per share expected for its FY13 and Q4FY13.

Despite continued strong volume growth, the Company believes there is an ongoing recalibration of reimbursement for the industry, which has resulted in substantial downward pressure from many payers regarding reimbursement in FY13. In addition, increased infrastructure expenses related to upgrading acquisitions in Florida and California and the launch of the Company's inherited cancer program that occurred too late in the period to meaningfully contribute to revenue in Q4FY13 also contributed to the results and for the quarter as well as guidance for the upcoming Fiscal Year.

Over the past year, the Company has had to negotiate contract modifications to reimbursement rates, conditions of payment and / or eligibility with dozens of health plans representing a substantial numbers of lives nationwide; most of these changes became effective toward the end of FY13 and especially in Q4FY13. The Company believes factors contributing to such pressure include the CMS proposed changes to reimbursements in July 2013, the changes in the Blue Card program, the tumult created in healthcare by the challenges of, and to, the Affordable Care Act and the three-week shutdown of the government.

In addition to reimbursement changes, the Company had significant additional expenses during the quarter resulting from several factors. The Company completed infrastructure expansions related to acquisitions in Florida and California, which the Company anticipates will result in an extraordinary one-time expense without offsetting revenue generation. Going forward, however, the Company expects to realize efficiencies and growth from the expanded infrastructure. There were also substantial start-up costs related to its GeneDx inherited cancer program, which includes tests for the BRCA genes; these expenses include substantial legal expenses associated with the roll-out and on-going defense of this program. The program was announced in late August and the Company has received highly favorable provider response and indications of acceptance. Nonetheless, the program did not have time to meaningfully contribute to Q4FY13 revenues although the Company anticipates this will be a strong program throughout FY2014.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,100.43 +62.46 0.35%
S&P 500 2,112.82 +3.90 0.18%
NASDAQ 5,069.6710 +9.4250 0.19%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs